Zidovudine Dose-Ranging Study for HIV Disease Management
Zidovudine
Blood-Borne Infections+14
+ Urogenital Diseases
+ Genital Diseases
Treatment Study
Summary
This study focuses on finding the right oral dose of a drug called zidovudine (AZT) for patients with HIV disease, specifically those in CDC Classification Groups IIB, III, and IV-C2. The drug has shown potential in reducing significant events and death in patients with AIDS, Pneumocystis carinii pneumonia (PCP), and AIDS related complex (ARC). The goal is to understand if AZT can be used effectively in all stages of HIV disease without causing significant toxicity. During the study, patients with documented HIV viremia who are in good health will receive AZT in increasing doses. The study measures the drug's toxicity, how well it reduces viremia, if it improves immune function, and if it prevents further manifestation of HIV disease. The drug levels in the patients will also be monitored and compared with the toxicity and viremia levels.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location